Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

Dr. Natasha Leighl's Highlights in Lung Cancer from 2012: Developments for EGFR Mutation-Positive NSCLC
Dr West
Author
Howard (Jack) West, MD

EGFR Mutn Pos NSCLCHere is the first of the awaited podcasts from Dr. Natasha Leighl's presentation on "Highlights in Lung Cancer from 2012".  Dr. Leighl is a longtime friend who is a lung cancer expert at Princess Margaret Hospital in Toronto, Ontario, Canada, and she covered a wide range of topics that represented promising developments in the field for the past year, some of which likely to lead to new treatment options for patients in the clinic over the next few years. 

The first part of her talk covered new information on potential treatment options for patients with advanced NSCLC that has an activating EGFR mutation.  Here's the video and audio versions of the podcast, along with the figures for it.  (We're going to forgo the transcript, since it's a time-consuming process, and I don't think there's a major audience for it -- tell us if there's a clear need for the transcripts for these programs that we're not seeing).

[powerpress]

Dr. Leighl Highlights in LC 2012: Pt 1 EGFR Mutn Pos Audio Podcast

Dr. Leighl Highlights in LC 2012 Pt 1 EGFR Mutn Pos Figures

We've got more parts of her presentation waiting in the wings, so check back for more highlights in lung cancer soon.

 

Next Previous link

Previous PostNext Post

Related Content

Online Community

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...

The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)

There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...

Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.

The...

Recent Comments

JOIN THE CONVERSATION
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on
A Brief Tornado.  I love the…
By JanineT GRACE … on
Biomarkers
By JanineT GRACE … on